Multicenter Real-World Study of Hyperthermia in Skin/Mucosal HPV Infection of Special Population

What this Trial Is About

This research aims to evaluate the effectiveness and safety of hyperthermia treatment for viral warts in special populations, including pregnant women, children, patients with autoimmune diseases, diabetes, and those on immunosuppressants after organ transplantation. Hyperthermia, a treatment using temperatures above normal body temperature, has shown promise in early studies by activating the body's immune response to remove HPV infection lesions. Prior research by this group indicated a 45-55% cure rate with hyperthermia, with benefits like no trauma, low recurrence, and good tolerance, leading to inclusion in medical guidelines and device registration for national promotion. The study uses an infrared hyperthermia device set at 44±1°C applied to lesions. Treatment involves three consecutive days of 30-minute sessions, followed by a break of 7-10 days, then two consecutive days of treatment, and subsequent sessions every 7-10 days. Lesion changes are assessed after 15 treatments to monitor the response to therapy. Participants will be monitored for cure and recurrence rates at three and six months, alongside rates of any adverse reactions. The study is conducted in multiple centers with real-world settings, focusing on this special population with viral warts. The total treatment and follow-up duration allow for assessing both short-term and longer-term outcomes of hyperthermia therapy for wart removal.

Multicenter Real-World Study of Hyperthermia in Warts of Special Population